source
- Biogen beats revenue expectations, lifts investor confidence with 3% sales riseBiogen reported $2.7 billion in revenue for the April‑June quarter, a 3% increase year over year, surpassing analysts' consensus estimate of $2.5 billion. Adjusted earnings per share came in at $3.…
- FDA advisory panel rejects Capricor’s Duchenne cardiomyopathy cell therapyA FDA advisory committee voted against Capricor’s cell therapy for Duchenne muscular dystrophy cardiomyopathy, with nine members opposing and three supporting the product. The therapy, called dera…